CPD Module - Fexofenadine

Allergy insights, Histallay Allergy Room

sponsored
cpc module

What you need to know about Histallay

This content is produced in partnership with Histallay

On December 22, 2020 the Medicines Healthcare and Regulatory Authority (MHRA) published a public assessment report reclassifying fexofenadine 120mg tablets from a prescription only medicine (POM) to general sales list (GSL). Fexofenadine is a non-sedating antihistamine, used to relieve symptoms of allergy such as hayfever, blocked nose and itchy or watery eyes.

Complete this CPD on the C+D Community

https://community.chemistanddruggist.co.uk/posts/cpd-module-fexofenadine?room_id=4400

Sign in or register for free

Latest from Learning

More from News